VolitionRx Limited (VNRX)
VolitionRx Limited (VNRX) Stock Price, Analysis & Data
| Bid | 0.65 |
| Market Cap | 7.8M |
| Revenue (ttm) | 2.47M |
| Net Income (ttm) | -24.6M |
| Beta | 1.14 |
| EPS (ttm) | -4.25 |
| PE Ratio (ttm) | n/a |
| Forward PE | -0.56 |
| P/B (ttm) | -0.16 |
| P/S (ttm) | 3.16 |
| Earnings Date | Aug 13, 2026 |
| Ask | 0.65 |
| Volume | 1,475,518 |
| Avg. Volume (20D) | 468,479 |
| Open | 0.76 |
| Previous Close | 0.72 |
| Day's Range | 0.63 - 0.78 |
| 52-Week Range | 0.63 - 15.20 |
| Analyst | n/a |
| Price Target | 20 (2976.92%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About VNRX
VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes. It also provides Nu.Q Cancer for predicting t...
Financial Performance
In 2025, VolitionRx's revenue was 1.73M, an increase of 40.04% compared to the previous year's 1.23M. Earnings were -23.36M, a decrease of -13.39%.
Financial StatementsAnalyst Forecast
According to 5 analyst ratings, the average rating for VNRX stock is "null". The 12-month stock price forecast is 20, which is upside of 2976.92% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
